Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun;17(6):317-319.
doi: 10.1200/OP.21.00111. Epub 2021 Apr 1.

Clinical and Psychosocial Challenges of Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years

Lubna N Chaudhary  1
Affiliations
Comment

Clinical and Psychosocial Challenges of Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years

Lubna N Chaudhary. JCO Oncol Pract. 2021 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Lubna N. ChaudharyConsulting or Advisory Role: Puma Biotechnology, Seattle GeneticsResearch Funding: RegeneronNo other potential conflicts of interest were reported.

Comment on

References

    1. Rosenberg SM, Partridge AH: Management of breast cancer in very young women. Breast 24:S154-S158, 2015. (suppl 2) - PubMed
    1. Cathcart-Rake EJ, Ruddy KJ, Bleyer A, et al. : Breast cancer in adolescent and young adult women under the age of 40 years. JCO Oncol Pract 17:305-313, 2021 - PubMed
    1. Sikov WM, Berry DA, Perou CM, et al. : Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33:13-21, 2015 - PMC - PubMed
    1. von Minckwitz G, Schneeweiss A, Loibl S, et al. : Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 15:747-756, 2014 - PubMed
    1. Schmid P, Cortes J, Pusztai L, et al. : Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810-821, 2020 - PubMed

Publication types